Corona Remedies acquires 7 brands from Bayer's pharma division in India
This marks the fourth acquisition by Corona Remedies from multinational corporations
This marks the fourth acquisition by Corona Remedies from multinational corporations
The primary purpose of this collaboration is to bring the optimized protein into the Indian market
The acquisition will strengthen Lupin’s India formulation business by adding a fast-growing portfolio of vitamins, minerals, supplements and neurological products
Subscribe To Our Newsletter & Stay Updated